Company: OFIX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061062
Chunk: 43

Company: Orthofix Medical Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 43
---
 director compensation programs and long-term incentive practices.

In connection with their engagement, Mercer and Meridian each reported to the Committee regarding their respective independence based on the six factors outlined in SEC regulations issued under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. The Committee considered these factors and concluded that both Mercer and Meridian are independent and that their respective engagement by the Committee raised no conflicts of interest.

Peer Group Benchmarking

Decisions related to executive compensation program design and pay levels are informed, in part, by the practices and pay levels of comparable peer organizations. The Committee engages its independent compensation consultant to conduct an annual executive compensation analysis that provides market competitive levels of total compensation. The assessment used in connection with setting 2024 compensation was provided by Mercer and compared the compensation levels of our Section 16 officers and members of our ELT with market data to determine whether their compensation levels remained consistent with market practice and our compensation philosophy. In conducting the assessment, Mercer made comparisons to our industry peer group and survey data including companies in the life sciences/medical devices industries.

<div align='center'>34</div>

In conducting the benchmarking for 2024 pay decisions, Mercer utilized a selection of 18 peer companies. The members of the peer group were selected for inclusion principally because of their overall similarity to Orthofix in terms of annual revenue, industry sector/sub-sector, medical technology product lines and international penetration. The peer group for 2024 pay decisions consisted of the following companies in the life sciences/medical devices industries, with whom we compete against for executive talent:

| Accuray Inc.           | Globus Medical Inc.                       |
| Alphatec Holdings Inc. | Haemonetics Corporation                   |
| AngioDynamics, Inc.    | Integer Holdings Corporation              |
| Artivion Inc.          | Integra LifeSciences Holdings Corporation |
| AtriCure, Inc.         | LivaNova PLC                              |
| Avanos Medical, Inc.   | Merit Medical Systems, Inc.               |
| Bioventus Inc.         | Nevro Corp.                               |
| CONMED Corporation     | NuVasive, Inc.(1)                         |
| Enovis Corporation     | ZimVie Inc.                               |

1 NuVasive, Inc. merged with Globus Medical in September 2023 The Role of Shareholder Say-on-Pay Votes The Company provides its shareholders with the opportunity to cast an annual advisory, non-binding vote on executive compensation (a “say-on-pay